S
SAB Biotherapeutics Inc
NASDAQ:SABS
SAB Biotherapeutics Inc
NASDAQ:SABS
Price:
3.74
USD
1.91%
Market Closed
Market Cap:
$178.1m
Relative Value
The Relative Value of one SABS stock under the Base Case scenario is hidden USD. Compared to the current market price of 3.74 USD, SAB Biotherapeutics Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SABS Relative Value
HIDDEN
Multiples Across Competitors
SABS Competitors Multiples
SAB Biotherapeutics Inc Competitors
SAB Biotherapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
S
|
SAB Biotherapeutics Inc
NASDAQ:SABS
|
177.6m USD | 1 548.6 | -8.3 | -1.8 | -1.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.2B USD | 6.7 | 171.3 | 16.6 | 23.5 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
206.8B USD | 5.6 | 26.9 | 15.3 | 15.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182.9B USD | 6.2 | 21.5 | 14.6 | 14.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.6B USD | 10.2 | 31.1 | 23.8 | 24.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.3B USD | 5.8 | 18.5 | 14 | 15.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.2B EUR | 13.8 | 32.5 | 55.4 | 57 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.7B AUD | 3.2 | 16.6 | 11.4 | 14.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
